Beta-blocker therapy at discharge improved survival and reduced adverse events in patients with ST-segment elevation myocardial infarction (STEMI) and reduced left ventricular ejection fraction (LVEF <40%). Results from this study were presented at the European Society of Cardiology (ESC) Congress 2025 from the Korea Acute Myocardial Infarction Registry (KAMIR).

The analysis included STEMI patients treated with drug-eluting stents. Groups were divided by beta-blocker use at discharge and balanced using inverse probability of treatment weighting. Outcomes were tracked for up to three years.

At one year, beta-blocker therapy lowered all-cause mortality (4.5% vs 7.4%; HR 0.58, 95% CI 0.43–0.78; p<0.001) and major adverse cardiac events (MACE: 9.3% vs 12.8%; HR 0.70, 95% CI 0.56–0.87; p=0.001). The benefit persisted at three years for both mortality (8.0% vs 11.2%; HR 0.68, 95% CI 0.54–0.86; p=0.002) and MACE (15.2% vs 18.6%; HR 0.78, 95% CI 0.65–0.94; p=0.009).

Beta-blocker therapy at discharge provided durable benefit in this high-risk group. The findings support its routine use in clinical practice.